Haploidentical bone marrow transplantation for @entity466 using XXXX agglutinin-negative, T-depleted marrow cells.

@entity1 @entity742 @entity1910 @entity2132 @entity1460 @entity11230 @entity466
The major limitation of mismatched bone marrow transplantation is fatal @entity2132 ( @entity2132 ). We processed haplotype-identical parental marrow with @entity1460 agglutinin (SBA), @entity742 erythrocytes (SRBC), and neuraminidase-treated SRBC (N-SRBC) to enrich for marrow stem cells and remove mature T cells. Nine @entity1 with @entity466 ( @entity466 ) who lacked histocompatible donors received these SBA-negative, SRBC-negative, N-SRBC-negative marrow transplants (0.5-5.0 X 10(8) cells/kg). Seven of the nine @entity1 (78%) had documented T-lymphocyte engraftment based on HLA typing and/or chromosomal analysis. Six @entity1 showed evidence of B-cell immunity on the basis of increased immunoglobulin levels, @entity11230 , and/or HLA-DR typing of non-T cells. Three @entity1 received marrow ablative chemotherapy pretransplant for maternal-fetal @entity2132 ; neutrophil engraftment occurred between 9 and 17 days posttransplantation, erythrocytes engrafted within 3-4 weeks of transplantation, and platelet recovery was seen between day 17 and day 49 following the transplants. No immunosuppression was given prophylactically posttransplant. Three @entity1 had no @entity2132 , two had transient @entity1910 and/or fever, and two developed mild focal (stage I) chronic cutaneous @entity2132 . Of the seven who engrafted, five (71%) are alive and clinically well without @entity2132 18-35 months posttransplant. These data demonstrate that SBA- and SRBC/N-SRBC-treated haploidentical marrow transplantation results in functional lymphocyte engraftment in @entity466 without significant @entity2132 , and can be used for some @entity1 who otherwise would have no hope for survival.
